HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-08-13

AUTHORS

Doug Coyle, Isabelle Durand-Zaleski, Jasmine Farrington, Louis Garrison, Johann-Matthias Graf von der Schulenburg, Wolfgang Greiner, Louise Longworth, Aurélie Meunier, Anne-Sophie Moutié, Stephen Palmer, Zack Pemberton-Whiteley, Mark Ratcliffe, Jie Shen, Doug Sproule, Kun Zhao, Koonal Shah

ABSTRACT

This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other’s constraints—limitations in the evidence generation on the manufacturer side, budget considerations on the payer side—and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years. More... »

PAGES

1421-1437

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w

DOI

http://dx.doi.org/10.1007/s10198-020-01212-w

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1130093751

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32794011


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell- and Tissue-Based Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Policy Making", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rare Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Technology Assessment, Biomedical", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Ottawa, Ottawa, Canada", 
          "id": "http://www.grid.ac/institutes/grid.28046.38", 
          "name": [
            "University of Ottawa, Ottawa, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coyle", 
        "givenName": "Doug", 
        "id": "sg:person.016420255222.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016420255222.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Paris Est, Champs-Sur-Marne, France", 
          "id": "http://www.grid.ac/institutes/grid.466400.0", 
          "name": [
            "University of Paris Est, Champs-Sur-Marne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Farrington", 
        "givenName": "Jasmine", 
        "id": "sg:person.015236747123.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015236747123.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington, Seattle, USA", 
          "id": "http://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garrison", 
        "givenName": "Louis", 
        "id": "sg:person.01002053374.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002053374.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Health Economics Research, Hannover, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Center for Health Economics Research, Hannover, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Graf von der Schulenburg", 
        "givenName": "Johann-Matthias", 
        "id": "sg:person.01331377620.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331377620.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bielefeld University, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7491.b", 
          "name": [
            "Bielefeld University, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greiner", 
        "givenName": "Wolfgang", 
        "id": "sg:person.01331127566.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331127566.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bielefeld University, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7491.b", 
          "name": [
            "Bielefeld University, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Longworth", 
        "givenName": "Louise", 
        "id": "sg:person.0752636034.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752636034.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meunier", 
        "givenName": "Aur\u00e9lie", 
        "id": "sg:person.014332745303.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014332745303.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mouti\u00e9", 
        "givenName": "Anne-Sophie", 
        "id": "sg:person.013455465123.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013455465123.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Health Economics, University of York, York, UK", 
          "id": "http://www.grid.ac/institutes/grid.5685.e", 
          "name": [
            "Center for Health Economics, University of York, York, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmer", 
        "givenName": "Stephen", 
        "id": "sg:person.012711633277.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012711633277.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pemberton-Whiteley", 
        "givenName": "Zack", 
        "id": "sg:person.07353705215.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07353705215.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ratcliffe", 
        "givenName": "Mark", 
        "id": "sg:person.011116672503.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011116672503.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shen", 
        "givenName": "Jie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AveXis, Chicago, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AveXis, Chicago, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sproule", 
        "givenName": "Doug", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "China National Health Development Research Center, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.433167.4", 
          "name": [
            "China National Health Development Research Center, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhao", 
        "givenName": "Kun", 
        "id": "sg:person.01322615152.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322615152.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shah", 
        "givenName": "Koonal", 
        "id": "sg:person.01172341334.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172341334.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12955-019-1189-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117679632", 
          "https://doi.org/10.1186/s12955-019-1189-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-018-1007-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107079490", 
          "https://doi.org/10.1007/s10198-018-1007-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-08-13", 
    "datePublishedReg": "2020-08-13", 
    "description": "This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other\u2019s constraints\u2014limitations in the evidence generation on the manufacturer side, budget considerations on the payer side\u2014and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10198-020-01212-w", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297512", 
        "issn": [
          "1439-3972", 
          "1439-6637"
        ], 
        "name": "The European Journal of Health Economics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "clinical efficacy data", 
      "ultra-rare disease", 
      "gene therapy", 
      "health technology assessment", 
      "cell-based therapies", 
      "efficacy data", 
      "therapy", 
      "healthcare budgets", 
      "clinical experts", 
      "success rate", 
      "reimbursement models", 
      "healthcare system", 
      "patients", 
      "evidence generation", 
      "development of cells", 
      "wider pathology", 
      "technology assessment", 
      "cells", 
      "HTA methodology", 
      "significant advances", 
      "disease", 
      "gene targeting", 
      "pathology", 
      "long-term durability", 
      "assessment", 
      "outcomes", 
      "payers", 
      "payer side", 
      "delivery", 
      "targeting", 
      "options", 
      "years", 
      "last decade", 
      "timely delivery", 
      "evaluation", 
      "benefits", 
      "rate", 
      "side", 
      "experts", 
      "barriers", 
      "challenges", 
      "advances", 
      "need", 
      "value assessment framework", 
      "extent", 
      "data", 
      "publications", 
      "development", 
      "potential", 
      "impact", 
      "decades", 
      "transformative benefits", 
      "system", 
      "consideration", 
      "research", 
      "point", 
      "model", 
      "manufacturers", 
      "making", 
      "generation", 
      "policy options", 
      "policy making", 
      "assessment framework", 
      "value framework", 
      "durability", 
      "methodology", 
      "price points", 
      "thinking", 
      "uncertainty", 
      "framework", 
      "innovative thinking", 
      "budget considerations", 
      "decision-making system", 
      "budget", 
      "sustainability", 
      "investment", 
      "higher price points", 
      "assets", 
      "development investment", 
      "manufacturer side", 
      "pricing", 
      "pipeline assets"
    ], 
    "name": "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies", 
    "pagination": "1421-1437", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1130093751"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10198-020-01212-w"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32794011"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10198-020-01212-w", 
      "https://app.dimensions.ai/details/publication/pub.1130093751"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_852.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10198-020-01212-w"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'


 

This table displays all metadata directly associated to this object as RDF triples.

317 TRIPLES      21 PREDICATES      118 URIs      106 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10198-020-01212-w schema:about N071b8e6eed3a4e44a59bc77cbc4da43a
2 N4725156c8caa4650a262a28845a76454
3 N73058901442e4e3381f3d0d1b10d08bf
4 N909b55e3c84642328b3bb6996ddd4a41
5 Nb0c0cb9df2c14e10889ca31d3a105fdb
6 Nb3e2aaf0f5344e3c8daf715b0fa7612c
7 Nec26b581e0734d1facc829b0e5344ca4
8 anzsrc-for:11
9 anzsrc-for:1117
10 anzsrc-for:14
11 anzsrc-for:1402
12 schema:author N66f3f8cb34284dfa8a9c5bdf5ea2175f
13 schema:citation sg:pub.10.1007/s10198-018-1007-x
14 sg:pub.10.1186/s12955-019-1189-7
15 schema:datePublished 2020-08-13
16 schema:datePublishedReg 2020-08-13
17 schema:description This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other’s constraints—limitations in the evidence generation on the manufacturer side, budget considerations on the payer side—and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years.
18 schema:genre article
19 schema:isAccessibleForFree false
20 schema:isPartOf N2745eb9a9f64426098fbc3d9981e31d4
21 Nb5fe8ba68ef74b919200597f44e481d9
22 sg:journal.1297512
23 schema:keywords HTA methodology
24 advances
25 assessment
26 assessment framework
27 assets
28 barriers
29 benefits
30 budget
31 budget considerations
32 cell-based therapies
33 cells
34 challenges
35 clinical efficacy data
36 clinical experts
37 consideration
38 data
39 decades
40 decision-making system
41 delivery
42 development
43 development investment
44 development of cells
45 disease
46 durability
47 efficacy data
48 evaluation
49 evidence generation
50 experts
51 extent
52 framework
53 gene targeting
54 gene therapy
55 generation
56 health technology assessment
57 healthcare budgets
58 healthcare system
59 higher price points
60 impact
61 innovative thinking
62 investment
63 last decade
64 long-term durability
65 making
66 manufacturer side
67 manufacturers
68 methodology
69 model
70 need
71 options
72 outcomes
73 pathology
74 patients
75 payer side
76 payers
77 pipeline assets
78 point
79 policy making
80 policy options
81 potential
82 price points
83 pricing
84 publications
85 rate
86 reimbursement models
87 research
88 side
89 significant advances
90 success rate
91 sustainability
92 system
93 targeting
94 technology assessment
95 therapy
96 thinking
97 timely delivery
98 transformative benefits
99 ultra-rare disease
100 uncertainty
101 value assessment framework
102 value framework
103 wider pathology
104 years
105 schema:name HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
106 schema:pagination 1421-1437
107 schema:productId N18253b221f1d4f48b7b2e6dbf61b6c40
108 N5829106907814060bd95011c397b4cbf
109 Ne09a34dc208043cb8dd21f9c594abafd
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130093751
111 https://doi.org/10.1007/s10198-020-01212-w
112 schema:sdDatePublished 2022-12-01T06:41
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher Nddaacb39f1634871ba1d57aef477177b
115 schema:url https://doi.org/10.1007/s10198-020-01212-w
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N02b09a9c70c14e1ebc5f42ecffb20688 rdf:first sg:person.015236747123.69
120 rdf:rest Naf372003fbed4ba3ba38ded226ec8378
121 N071b8e6eed3a4e44a59bc77cbc4da43a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Policy Making
123 rdf:type schema:DefinedTerm
124 N18253b221f1d4f48b7b2e6dbf61b6c40 schema:name dimensions_id
125 schema:value pub.1130093751
126 rdf:type schema:PropertyValue
127 N19f2ea3d2b7d4be5bd63e330df57099a schema:affiliation grid-institutes:None
128 schema:familyName Sproule
129 schema:givenName Doug
130 rdf:type schema:Person
131 N2745eb9a9f64426098fbc3d9981e31d4 schema:volumeNumber 21
132 rdf:type schema:PublicationVolume
133 N31003632db7b4bde9206c9c50ce5276a rdf:first N79ac64fb8d6143df9f49e927c6a9392e
134 rdf:rest N572c38966b874c62a2f6525aceb501c5
135 N413dd261d0a84eac8a22103a06612a86 rdf:first sg:person.07353705215.15
136 rdf:rest N6894040bd8bc4e0697f3af664522138c
137 N4725156c8caa4650a262a28845a76454 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Cell- and Tissue-Based Therapy
139 rdf:type schema:DefinedTerm
140 N544e3d988c654edc97d1bcd9a3944b5d rdf:first sg:person.01331377620.80
141 rdf:rest Na5caf43ee4e04b70ae27e4b338c12a4d
142 N572c38966b874c62a2f6525aceb501c5 rdf:first N19f2ea3d2b7d4be5bd63e330df57099a
143 rdf:rest Nd0ee7eb9d991437091fdd7c03f3c24cb
144 N5829106907814060bd95011c397b4cbf schema:name pubmed_id
145 schema:value 32794011
146 rdf:type schema:PropertyValue
147 N6078b10ddef5493899dda4fff3f277f1 rdf:first sg:person.012711633277.14
148 rdf:rest N413dd261d0a84eac8a22103a06612a86
149 N66f3f8cb34284dfa8a9c5bdf5ea2175f rdf:first sg:person.016420255222.13
150 rdf:rest N7e658837b9db415a83c012bc74d0b1e0
151 N6894040bd8bc4e0697f3af664522138c rdf:first sg:person.011116672503.34
152 rdf:rest N31003632db7b4bde9206c9c50ce5276a
153 N73058901442e4e3381f3d0d1b10d08bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Technology Assessment, Biomedical
155 rdf:type schema:DefinedTerm
156 N79ac64fb8d6143df9f49e927c6a9392e schema:affiliation grid-institutes:grid.419481.1
157 schema:familyName Shen
158 schema:givenName Jie
159 rdf:type schema:Person
160 N7bda2d8139a649909ae0758bbc8f54d5 rdf:first sg:person.01172341334.33
161 rdf:rest rdf:nil
162 N7e658837b9db415a83c012bc74d0b1e0 rdf:first sg:person.01327533357.46
163 rdf:rest N02b09a9c70c14e1ebc5f42ecffb20688
164 N7f3ef02f46c548d0ac2526d1e23a9012 rdf:first sg:person.0752636034.37
165 rdf:rest Ne150368351a9406d9661ae9f64eba10f
166 N909b55e3c84642328b3bb6996ddd4a41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Cost-Benefit Analysis
168 rdf:type schema:DefinedTerm
169 N920da3b392a2464aa3beb3c182f835c3 rdf:first sg:person.013455465123.21
170 rdf:rest N6078b10ddef5493899dda4fff3f277f1
171 Na5caf43ee4e04b70ae27e4b338c12a4d rdf:first sg:person.01331127566.82
172 rdf:rest N7f3ef02f46c548d0ac2526d1e23a9012
173 Naf372003fbed4ba3ba38ded226ec8378 rdf:first sg:person.01002053374.17
174 rdf:rest N544e3d988c654edc97d1bcd9a3944b5d
175 Nb0c0cb9df2c14e10889ca31d3a105fdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Humans
177 rdf:type schema:DefinedTerm
178 Nb3e2aaf0f5344e3c8daf715b0fa7612c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Genetic Therapy
180 rdf:type schema:DefinedTerm
181 Nb5fe8ba68ef74b919200597f44e481d9 schema:issueNumber 9
182 rdf:type schema:PublicationIssue
183 Nd0ee7eb9d991437091fdd7c03f3c24cb rdf:first sg:person.01322615152.98
184 rdf:rest N7bda2d8139a649909ae0758bbc8f54d5
185 Nddaacb39f1634871ba1d57aef477177b schema:name Springer Nature - SN SciGraph project
186 rdf:type schema:Organization
187 Ne09a34dc208043cb8dd21f9c594abafd schema:name doi
188 schema:value 10.1007/s10198-020-01212-w
189 rdf:type schema:PropertyValue
190 Ne150368351a9406d9661ae9f64eba10f rdf:first sg:person.014332745303.05
191 rdf:rest N920da3b392a2464aa3beb3c182f835c3
192 Nec26b581e0734d1facc829b0e5344ca4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Rare Diseases
194 rdf:type schema:DefinedTerm
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
199 schema:name Public Health and Health Services
200 rdf:type schema:DefinedTerm
201 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
202 schema:name Economics
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
205 schema:name Applied Economics
206 rdf:type schema:DefinedTerm
207 sg:journal.1297512 schema:issn 1439-3972
208 1439-6637
209 schema:name The European Journal of Health Economics
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.01002053374.17 schema:affiliation grid-institutes:grid.34477.33
213 schema:familyName Garrison
214 schema:givenName Louis
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002053374.17
216 rdf:type schema:Person
217 sg:person.011116672503.34 schema:affiliation grid-institutes:None
218 schema:familyName Ratcliffe
219 schema:givenName Mark
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011116672503.34
221 rdf:type schema:Person
222 sg:person.01172341334.33 schema:affiliation grid-institutes:None
223 schema:familyName Shah
224 schema:givenName Koonal
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172341334.33
226 rdf:type schema:Person
227 sg:person.012711633277.14 schema:affiliation grid-institutes:grid.5685.e
228 schema:familyName Palmer
229 schema:givenName Stephen
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012711633277.14
231 rdf:type schema:Person
232 sg:person.01322615152.98 schema:affiliation grid-institutes:grid.433167.4
233 schema:familyName Zhao
234 schema:givenName Kun
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322615152.98
236 rdf:type schema:Person
237 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.466400.0
238 schema:familyName Durand-Zaleski
239 schema:givenName Isabelle
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
241 rdf:type schema:Person
242 sg:person.01331127566.82 schema:affiliation grid-institutes:grid.7491.b
243 schema:familyName Greiner
244 schema:givenName Wolfgang
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331127566.82
246 rdf:type schema:Person
247 sg:person.01331377620.80 schema:affiliation grid-institutes:None
248 schema:familyName Graf von der Schulenburg
249 schema:givenName Johann-Matthias
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331377620.80
251 rdf:type schema:Person
252 sg:person.013455465123.21 schema:affiliation grid-institutes:None
253 schema:familyName Moutié
254 schema:givenName Anne-Sophie
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013455465123.21
256 rdf:type schema:Person
257 sg:person.014332745303.05 schema:affiliation grid-institutes:None
258 schema:familyName Meunier
259 schema:givenName Aurélie
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014332745303.05
261 rdf:type schema:Person
262 sg:person.015236747123.69 schema:affiliation grid-institutes:None
263 schema:familyName Farrington
264 schema:givenName Jasmine
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015236747123.69
266 rdf:type schema:Person
267 sg:person.016420255222.13 schema:affiliation grid-institutes:grid.28046.38
268 schema:familyName Coyle
269 schema:givenName Doug
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016420255222.13
271 rdf:type schema:Person
272 sg:person.07353705215.15 schema:affiliation grid-institutes:None
273 schema:familyName Pemberton-Whiteley
274 schema:givenName Zack
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07353705215.15
276 rdf:type schema:Person
277 sg:person.0752636034.37 schema:affiliation grid-institutes:grid.7491.b
278 schema:familyName Longworth
279 schema:givenName Louise
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752636034.37
281 rdf:type schema:Person
282 sg:pub.10.1007/s10198-018-1007-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1107079490
283 https://doi.org/10.1007/s10198-018-1007-x
284 rdf:type schema:CreativeWork
285 sg:pub.10.1186/s12955-019-1189-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117679632
286 https://doi.org/10.1186/s12955-019-1189-7
287 rdf:type schema:CreativeWork
288 grid-institutes:None schema:alternateName Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland
289 AveXis, Chicago, USA
290 Center for Health Economics Research, Hannover, Hannover, Germany
291 PHMR Ltd, London, UK
292 schema:name Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland
293 AveXis, Chicago, USA
294 Center for Health Economics Research, Hannover, Hannover, Germany
295 PHMR Ltd, London, UK
296 rdf:type schema:Organization
297 grid-institutes:grid.28046.38 schema:alternateName University of Ottawa, Ottawa, Canada
298 schema:name University of Ottawa, Ottawa, Canada
299 rdf:type schema:Organization
300 grid-institutes:grid.34477.33 schema:alternateName University of Washington, Seattle, USA
301 schema:name University of Washington, Seattle, USA
302 rdf:type schema:Organization
303 grid-institutes:grid.419481.1 schema:alternateName Novartis, Basel, Switzerland
304 schema:name Novartis, Basel, Switzerland
305 rdf:type schema:Organization
306 grid-institutes:grid.433167.4 schema:alternateName China National Health Development Research Center, Beijing, China
307 schema:name China National Health Development Research Center, Beijing, China
308 rdf:type schema:Organization
309 grid-institutes:grid.466400.0 schema:alternateName University of Paris Est, Champs-Sur-Marne, France
310 schema:name University of Paris Est, Champs-Sur-Marne, France
311 rdf:type schema:Organization
312 grid-institutes:grid.5685.e schema:alternateName Center for Health Economics, University of York, York, UK
313 schema:name Center for Health Economics, University of York, York, UK
314 rdf:type schema:Organization
315 grid-institutes:grid.7491.b schema:alternateName Bielefeld University, Bielefeld, Germany
316 schema:name Bielefeld University, Bielefeld, Germany
317 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...